PharmaGossip (Free subscription) | yesterday
When chief executive David Mott packs up his desk July 31 after 16 years at MedImmune he won't be alone. Without the official AZ press release that accompanied Mott's announced departure on June 26, two other high-level executives have quietly left. Jim Young, president of research and development, and Ed Mathers, executive vice president of corporate development and ventures, left in June. Young had...
Patent Docs (Free subscription) | yesterday
By Sherri Oslick -- Late last week, Judge Pisano of the District Court of New Jersey granted summary judgment of no inequitable conduct in favor of AstraZeneca in its consolidated Paragraph IV litigation against Teva Pharmaceuticals and Sandoz, Inc. over AstraZeneca's antipsychotic drug Seroquel®. Because the Defendants previously abandoned their other defenses, no issues remain for trial; AstraZeneca...
Market Watch (Free subscription) | 07/07/2008
LONDON (MarketWatch) -- Deutsche Bank downgraded AstraZeneca to hold from buy, saying the positive resolution of the U.S. patent litigation against both Nexium and Seroquel has removed the two most important near-term threats to the company. "Following 24% outperformance vs the FTSE 100 year-to-date, the stock is trading within the region of fair value on our assessment, and with fewer important catalysts...
AAPL - BloggingStocks (Free subscription) | 07/07/2008
Filed under: Before the bell , Analyst upgrades and downgrades , Apple Inc (AAPL) , Merck and Co (MRK) , Broadcom Corp'A' (BRCM) Deutsche Bank downgraded AstraZeneca (NYSE: AZN ) to "hold" from "buy", according to MarketWatch. Lehman Brothers reiterated its "overweight" rating on Apple (NASDAQ: AAPL ) ahead of the 3G iPhone going on sale, according to the AP. UBS downgraded Merck (NYSE: MRK ) from...
soulful sepulcher (Free subscription) | 07/05/2008
Good news everyone! AstraZeneca won a battle in court to keep the patent, and not go generic! The high priced antipsychotic can safely remain on the market at name brand cost, medicate children, anxiety, depression and more! This just makes me so happy for AZ that I want to re-post my poem I wrote about Seroquel. Don't ya love name brands? this is an antipsychotic, and ingredients have been
Medical News Today (Free subscription) | 07/04/2008
AstraZeneca announced the online publication of long-term SEROQUEL® (quetiapine fumarate) clinical trial data in the Journal of Affective Disorders. Results show that SEROQUEL in combination with lithium or divalproex significantly increased the time to recurrence of any mood event in patients with bipolar I disorder compared with lithium or divalproex alone.
NC Mental Hope News (Free subscription) | 07/03/2008
LONDON (Reuters) - AstraZeneca (AZN.L: Quote, Profile, Research) shares rose nearly 5 percent on Wednesday after the group won a key U.S. patent battle over its second-biggest selling drug, Seroquel, for schizophrenia and bipolar disorder. The court decision to award summary judgment in its favour, thus avoiding the need for a lengthy trial, underpins future profits by making it highly unlikely
The Independent (Free subscription) | 07/03/2008
Anglo-Swedish pharmaceutical group AstraZeneca received a boost yesterday when a US court upheld its patent over $4bn a year schizophrenia and bipolar blockbuster Seroquel.
Financial Time (Free subscription) | 07/02/2008
Shares in AstraZeneca rose nearly 5 per cent on Wednesday after a US legal ruling pushed back the likely launch of a generic version of Seroquel, its blockbuster schizophrenia medicine, until 2011
Inbox Robot: Swiss Reinsurance News (Free subscription) | 07/02/2008
Astra shares up 6 pct on Seroquel court ruling (AP) LONDON - Shares in AstraZeneca PLC jumped 6 percent Wednesday after the drug maker won a
Inbox Robot: Swiss Reinsurance News (Free subscription) | 07/02/2008
LONDON (AP) - Shares in AstraZeneca PLC jumped 6 percent on Wednesday after the drug maker won a key patent battle in the United States over
Market Watch (Free subscription) | 07/02/2008
U.K. drug manufacturer AstraZeneca has won a major court decision in its ongoing battle to ward off generic versions of its widely prescribed antipsychotic drug Seroquel in the U.S.
Market Watch (Free subscription) | 07/02/2008
BOSTON (MarketWatch)-- Drug stocks edged higher in early action Wednesday as shares of AstraZeneca PLC gained on news that it had won a significant court decision that should help ward off generic competition for its drug Seroquel in the U.S. until around 2011. The Amex Pharmaceutical Index and the Amex Biotechnology Index were both up marginally at 293.4 and 750.0, respectively. AstraZeneca shares...
IPBiz (Free subscription) | 07/02/2008
U.S. District Judge Joel Pisano in Trenton, New Jersey ruled in favor of AstraZeneca in the Seroquel matter on July 1, and AstraZeneca can ask Judge Pisano to block Teva and Sandoz from getting U.S. regulatory approval to sell copies of Seroquel until the patent expires in 2011. Bloomberg noted: AstraZeneca is trying to broaden Seroquel's use to keep revenue rising as sales of its No. 1 product, the...
Law Blog - WSJ.com (Free subscription) | 07/02/2008
AstraZeneca won an important court decision that will likely delay U.S. generic competition to the company's top-selling schizophrenia drug Seroquel until 2011.
The last article published by a user on AstraZeneca :
sunilnair | 12/25/2007
AstraZeneca plc (incl. MedImmune Inc.): PharmaVitae Profile Introduction This analysis examines the historical and forecast performance for AstraZeneca in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool...
